TY - JOUR
T1 - Medical management to prevent recurrent nephrolithiasis in adults
T2 - A systematic review for an American College of Physicians Clinical Guideline
AU - Fink, Howard A.
AU - Wilt, Timothy J.
AU - Eidman, Keith E.
AU - Garimella, Pranav S.
AU - MacDonald, Roderick
AU - Rutks, Indulis R.
AU - Brasure, Michelle
AU - Kane, Robert L.
AU - Ouellette, Jeannine
AU - Monga, Manoj
PY - 2013/4/2
Y1 - 2013/4/2
N2 - Background: Optimum management to prevent recurrent kidney stones is uncertain. Purpose: To evaluate the benefits and harms of interventions to prevent recurrent kidney stones. Data Sources: MEDLINE, Cochrane, and other databases through September 2012 and reference lists of systematic reviews and ran-domized, controlled trials (RCTs). Study Selection: 28 English-language RCTs that studied treatments to prevent recurrent kidney stones and reported stone outcomes. Data Extraction: One reviewer extracted data, a second checked accuracy, and 2 independently rated quality and graded strength of evidence. Data Synthesis: In patients with 1 past calcium stone, low-strength evidence showed that increased fluid intake halved recurrent com-posite stone risk compared with no treatment (relative risk [RR], 0.45 [95% CI, 0.24 to 0.84]). Low-strength evidence showed that reducing soft-drink consumption decreased recurrent symptomatic stone risk (RR, 0.83 [CI, 0.71 to 0.98]). In patients with multiple past calcium stones, most of whom were receiving increased fluid intake, moderate-strength evidence showed that thiazides (RR, 0.52 [CI, 0.39 to 0.69]), citrates (RR, 0.25 [CI, 0.14 to 0.44]), and allopurinol (RR, 0.59 [CI, 0.42 to 0.84]) each further reduced com-posite stone recurrence risk compared with placebo or control, although the benefit from allopurinol seemed limited to patients with baseline hyperuricemia or hyperuricosuria. Other baseline bio-chemistry measures did not allow prediction of treatment efficacy. Low-strength evidence showed that neither citrate nor allopurinol combined with thiazide was superior to thiazide alone. There were few withdrawals among patients with increased fluid intake, many among those with other dietary interventions and more among those who received thiazide and citrate than among control pa-tients. Reporting of adverse events was poor. Limitations: Most trial participants had idiopathic calcium stones. Nearly all studies reported a composite (including asymptomatic) stone recurrence outcome. Conclusion: In patients with 1 past calcium stone, increased fluid intake reduced recurrence risk. In patients with multiple past cal-cium stones, addition of thiazide, citrate, or allopurinol further re-duced risk. Primary Funding Source: Agency for Healthcare Research and Quality.
AB - Background: Optimum management to prevent recurrent kidney stones is uncertain. Purpose: To evaluate the benefits and harms of interventions to prevent recurrent kidney stones. Data Sources: MEDLINE, Cochrane, and other databases through September 2012 and reference lists of systematic reviews and ran-domized, controlled trials (RCTs). Study Selection: 28 English-language RCTs that studied treatments to prevent recurrent kidney stones and reported stone outcomes. Data Extraction: One reviewer extracted data, a second checked accuracy, and 2 independently rated quality and graded strength of evidence. Data Synthesis: In patients with 1 past calcium stone, low-strength evidence showed that increased fluid intake halved recurrent com-posite stone risk compared with no treatment (relative risk [RR], 0.45 [95% CI, 0.24 to 0.84]). Low-strength evidence showed that reducing soft-drink consumption decreased recurrent symptomatic stone risk (RR, 0.83 [CI, 0.71 to 0.98]). In patients with multiple past calcium stones, most of whom were receiving increased fluid intake, moderate-strength evidence showed that thiazides (RR, 0.52 [CI, 0.39 to 0.69]), citrates (RR, 0.25 [CI, 0.14 to 0.44]), and allopurinol (RR, 0.59 [CI, 0.42 to 0.84]) each further reduced com-posite stone recurrence risk compared with placebo or control, although the benefit from allopurinol seemed limited to patients with baseline hyperuricemia or hyperuricosuria. Other baseline bio-chemistry measures did not allow prediction of treatment efficacy. Low-strength evidence showed that neither citrate nor allopurinol combined with thiazide was superior to thiazide alone. There were few withdrawals among patients with increased fluid intake, many among those with other dietary interventions and more among those who received thiazide and citrate than among control pa-tients. Reporting of adverse events was poor. Limitations: Most trial participants had idiopathic calcium stones. Nearly all studies reported a composite (including asymptomatic) stone recurrence outcome. Conclusion: In patients with 1 past calcium stone, increased fluid intake reduced recurrence risk. In patients with multiple past cal-cium stones, addition of thiazide, citrate, or allopurinol further re-duced risk. Primary Funding Source: Agency for Healthcare Research and Quality.
UR - http://www.scopus.com/inward/record.url?scp=84875753302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875753302&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-158-7-201304020-00005
DO - 10.7326/0003-4819-158-7-201304020-00005
M3 - Review article
C2 - 23546565
AN - SCOPUS:84875753302
SN - 0003-4819
VL - 158
SP - 535
EP - 543
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 7
ER -